{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:55:10Z","timestamp":1777859710401,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T00:00:00Z","timestamp":1423094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2015,6]]},"abstract":"\n Objective:<\/jats:title>\n To describe 2 cases of drug-induced eosinophilic pneumonia in patients with variable exposure to daptomycin.<\/jats:p>\n <\/jats:sec>\n \n Report:<\/jats:title>\n In our first case, a 77-year-old male was transferred to our facility for hypoxic respiratory failure, which occurred 1 day after completing a course of daptomycin. There was high clinical suspicion for daptomycin-induced eosinophilic pneumonia, thus the patient was started on intravenous methylprednisolone 40 mg every 6 hours. Within 72 hours, he was liberated from mechanical ventilation, as he experienced dramatic clinical improvement in regard to his oxygenation and radiographs. Approximately 6 weeks after case 1, a second case of eosinophilic pneumonia related to daptomycin was diagnosed. This case occurred in a 74-year-old female who developed respiratory failure requiring noninvasive positive pressure ventilation 72 hours after initiation of a second course of daptomycin. She was treated with methylprednisolone 60 mg every 6 hours and avoided the need for endotracheal intubation and mechanical ventilation.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Since this potentially life-threatening adverse effect of daptomycin appears more common than previously reported, clinicians should have a high level of suspicion in any patient with recent daptomycin exposure who presents with pulmonary symptoms. In many cases, this process is highly responsive to prompt initiation of corticosteroid therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/0897190014568678","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T23:13:36Z","timestamp":1423178016000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Daptomycin-Induced Eosinophilic Pneumonia Treated With Intravenous Corticosteroids"],"prefix":"10.1177","volume":"28","author":[{"given":"Shao-Yu","family":"Chiu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Faust","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant M.","family":"Dand","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Pulmonary Disease, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,2,5]]},"reference":[{"key":"bibr1-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.5.7952571"},{"key":"bibr2-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939522"},{"key":"bibr3-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2006.11.006"},{"key":"bibr4-0897190014568678","unstructured":"Camus P, Foucher P. The drug-induced respiratory disease website [Internet]. Dijon, France; 2012. Web site. www.pneumotox.com. Published June 10, 2012. Updated July 11, 2014."},{"key":"bibr5-0897190014568678","unstructured":"Cubicin\n \u00ae\n (daptomycin) [package insert]. Lexington, MA: Cubist Pharmaceuticals; Revised January 2013."},{"key":"bibr6-0897190014568678","doi-asserted-by":"publisher","DOI":"10.2165\/11597460-000000000-00000"},{"key":"bibr7-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00057903"},{"key":"bibr8-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2112056"},{"key":"bibr9-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1086\/652656"},{"key":"bibr10-0897190014568678","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2013.805427"},{"key":"bibr11-0897190014568678","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-5-13"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190014568678","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190014568678","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190014568678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:10Z","timestamp":1777509370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190014568678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,5]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1177\/0897190014568678"],"URL":"https:\/\/doi.org\/10.1177\/0897190014568678","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,5]]}}}